Onconic Therapeutics - Public Comps and Valuation Multiples

Onconic Therapeutics Overview

About Onconic Therapeutics

Onconic Therapeutics Inc is a company that researches and develops new drugs for gastrointestinal diseases and anticancers, which have large unmet medical needs. Its pipeline products are Zataprazan(OCN-101) and OCN-201.

Founded

2020

HQ

Employees

n/a

Website

onconic.co.kr

Sectors

Biopharmaceuticals
Drug Delivery Systems
BioTech

Financials

LTM Revenue $37.3M

LTM EBITDA $9.7M

EV

$578M

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Onconic Therapeutics Financials

As of December 2025, Onconic Therapeutics reported last 12-month revenue of $37.3M and EBITDA of $9.7M.

In the same period, Onconic Therapeutics achieved $9.6M in LTM net income.

See Onconic Therapeutics valuation multiples based on analyst estimates

Onconic Therapeutics P&L

In the most recent fiscal year, Onconic Therapeutics reported revenue of $10.2M and EBITDA of -$6.1M.

Onconic Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Onconic Therapeutics valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2026	FY 2027	FY 2028
Revenue	$37.3M	XXX	$10.2M	XXX	XXX	XXX
Gross Profit	n/a	XXX	$10.2M	XXX	XXX	XXX
Gross Margin	n/a	XXX	100%	XXX	XXX	XXX
EBITDA	$9.7M	XXX	-$6.1M	XXX	XXX	XXX
EBITDA Margin	26%	XXX	-59%	XXX	XXX	XXX
EBIT	$9.3M	XXX	-$3.3M	XXX	XXX	XXX
EBIT Margin	25%	XXX	-32%	XXX	XXX	XXX
Net Profit	$9.6M	XXX	-$5.6M	XXX	XXX	XXX
Net Margin	26%	XXX	-55%	XXX	XXX	XXX
Net Debt	XXX	XXX	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Onconic Therapeutics including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $37.3M. EBITDA for the last twelve months was $9.7M. In the most recent fiscal year, Onconic Therapeutics achieved $10.2M in revenue and -$6.1M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2026)	Next Fiscal Year (2027)	Two Years Forward (2028)
Total Revenue	$37.3M	Analyst estimates available to subscribers	$10.2M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	n/a	Analyst estimates available to subscribers	$10.2M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	n/a	Analyst estimates available to subscribers	100.0% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	$9.7M	Analyst estimates available to subscribers	-$6.1M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	25.9% EBITDA margin	Analyst estimates available to subscribers	-59.5% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	$9.3M	Analyst estimates available to subscribers	-$3.3M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	25.0% EBIT margin	Analyst estimates available to subscribers	-32.3% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	$9.6M	Analyst estimates available to subscribers	-$5.6M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	25.7% net profit margin	Analyst estimates available to subscribers	-54.5% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	n/a	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Onconic Therapeutics

This financial data table provides comprehensive performance metrics for Onconic Therapeutics, a company based in South Korea. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

Onconic Therapeutics generated $37.3M in revenue over the last twelve months.
The company achieved $9.7M in EBITDA over the last twelve months.
Net income over the last twelve months reached $9.6M.

Fiscal Year Performance

In the most recent fiscal year, Onconic Therapeutics reported $10.2M in total revenue.
Fiscal year EBITDA was -$6.1M.
The company maintained a gross profit margin of 100.0% in the most recent fiscal year.
EBITDA margin for the fiscal year was -59.5%.
Net profit margin reached -54.5% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Onconic Therapeutics. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Onconic Therapeutics Stock Performance

Onconic Therapeutics has current market cap of KRW 891B (or $615M), and EV of KRW 838B (or $578M).

Market Cap Evolution

Onconic Therapeutics Stock Data

As of January 16, 2026, Onconic Therapeutics's stock price is KRW 20050 (or $14).

See Onconic Therapeutics trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$578M	$615M	XXX	XXX	XXX	XXX	$0.22

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Onconic Therapeutics Valuation Multiples

Onconic Therapeutics's trades at 15.5x EV/Revenue multiple, and 59.8x EV/EBITDA.

See valuation multiples for Onconic Therapeutics and 15K+ public comps

Onconic Therapeutics Financial Valuation Multiples

As of January 16, 2026, Onconic Therapeutics has market cap of $615M and EV of $578M.

Equity research analysts estimate Onconic Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Onconic Therapeutics has a P/E ratio of 64.1x.

	LTM	NTM	Last FY	FY 2026	FY 2027	FY 2028
Market cap (current)	$615M	XXX	$615M	XXX	XXX	XXX
EV (current)	$578M	XXX	$578M	XXX	XXX	XXX
EV/Revenue	15.5x	XXX	15.5x	XXX	XXX	XXX
EV/EBITDA	59.8x	XXX	59.8x	XXX	XXX	XXX
EV/EBIT	62.1x	XXX	62.1x	XXX	XXX	XXX
EV/Gross Profit	n/a	XXX	n/a	XXX	XXX	XXX
P/E	64.1x	XXX	64.1x	XXX	XXX	XXX
EV/FCF	n/a	XXX	-105.0x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Onconic Therapeutics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Onconic Therapeutics Margins & Growth Rates

Onconic Therapeutics's last 12 month revenue growth is 64%

Onconic Therapeutics's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.

Onconic Therapeutics's rule of 40 is 78% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Onconic Therapeutics's rule of X is 186% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Onconic Therapeutics and other 15K+ public comps

Onconic Therapeutics Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2026	FY 2027	FY 2028
Revenue Growth	64%	XXX	42%	XXX	XXX	XXX
EBITDA Margin	26%	XXX	26%	XXX	XXX	XXX
EBITDA Growth	100%	XXX	120%	XXX	XXX	XXX
Rule of 40	78%	XXX	90%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	186%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	n/a	XXX	XXX	XXX
Opex per Employee	XXX	XXX	n/a	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	12%	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	74%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	132%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial